Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2015
Price : $35 *
At a glance
- Drugs Anakinra (Primary)
- Indications Mucocutaneous lymph node syndrome
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 23 Dec 2014 Planned End Date changed from 1 Dec 2017 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020 as reported by ClinicalTrials.gov record.